(1.26%) 5 127.78 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.03%) $78.14
(5.45%) $2.15
(-0.03%) $2 308.80
(-0.31%) $26.75
(0.19%) $964.45
(-0.34%) $0.929
(-1.12%) $10.87
(-0.13%) $0.797
(0.39%) $91.49
Live Chart Being Loaded With Signals
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer...
Stats | |
---|---|
Dagens volum | 16 865.00 |
Gjennomsnittsvolum | 20 800.00 |
Markedsverdi | 20.39M |
EPS | $0 ( 2024-02-08 ) |
Neste inntjeningsdato | ( $-1.520 ) 2024-05-09 |
Last Dividend | $1.750 ( 2023-11-16 ) |
Next Dividend | $0 ( N/A ) |
P/E | 1.030 |
ATR14 | $0.0250 (0.82%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-18 | Flynn James P | Buy | 10 000 | Stock Option (Right to Buy) |
2023-12-18 | Flynn James P | Buy | 6 700 | Stock Option (Right to Buy) |
2023-12-18 | Wood Steven D | Buy | 10 000 | Stock Option (Right to Buy) |
2023-12-18 | Wood Steven D | Buy | 6 700 | Stock Option (Right to Buy) |
2023-12-18 | Wood Steven D | Buy | 10 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
92.96 |
Last 96 transactions |
Buy: 9 932 993 | Sell: 849 643 |
MEI Pharma Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
RIDE | 0.969 |
IMBI | 0.968 |
ASLE | 0.962 |
EVOK | 0.961 |
EBIX | 0.961 |
VRAY | 0.96 |
TBLT | 0.958 |
MSEX | 0.955 |
AGRI | 0.947 |
CFRX | 0.947 |
10 Mest negative korrelasjoner | |
---|---|
VMGA | -0.965 |
ADAL | -0.965 |
HCNE | -0.959 |
BRIV | -0.959 |
TIOAU | -0.958 |
VLAT | -0.958 |
RNLC | -0.956 |
KVSC | -0.955 |
EGLE | -0.955 |
LDHA | -0.954 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
MEI Pharma Inc Økonomi
Annual | 2023 |
Omsetning: | $48.82M |
Bruttogevinst: | $47.00M (96.28 %) |
EPS: | $-4.78 |
FY | 2023 |
Omsetning: | $48.82M |
Bruttogevinst: | $47.00M (96.28 %) |
EPS: | $-4.78 |
FY | 2022 |
Omsetning: | $40.70M |
Bruttogevinst: | $39.46M (96.97 %) |
EPS: | $-8.80 |
FY | 2021 |
Omsetning: | $25.54M |
Bruttogevinst: | $24.13M (94.49 %) |
EPS: | $-0.450 |
Financial Reports:
No articles found.
MEI Pharma Inc Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$1.750 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $1.750 | 2023-11-16 |
Last Dividend | $1.750 | 2023-11-16 |
Next Dividend | $0 | N/A |
Payout Date | 2023-12-06 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $1.750 | -- |
Avg. Dividend % Per Year | 11.67% | -- |
Score | 4.75 | -- |
Div. Sustainability Score | 5.51 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 2.48 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $1.750 | 35.00% |
2024 | $0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.286 | 1.500 | 4.27 | 6.41 | [0 - 0.5] |
returnOnAssetsTTM | 0.265 | 1.200 | 1.173 | 1.408 | [0 - 0.3] |
returnOnEquityTTM | 0.416 | 1.500 | 6.49 | 9.73 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 8.23 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 7.40 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.644 | 1.500 | 7.54 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.153 | -1.500 | 7.45 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -16.44 | 1.000 | -7.20 | -7.20 | [3 - 30] |
operatingCashFlowPerShareTTM | -7.95 | 2.00 | -2.65 | -5.30 | [0 - 30] |
freeCashFlowPerShareTTM | -7.95 | 2.00 | -3.97 | -7.95 | [0 - 20] |
debtEquityRatioTTM | 0.202 | -1.500 | 9.19 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.980 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.219 | 1.000 | 7.63 | 7.63 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -4.40 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.925 | 0.800 | 7.17 | 5.73 | [0.5 - 2] |
Total Score | 5.51 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 0.980 | 1.000 | -0.00198 | 0 | [1 - 100] |
returnOnEquityTTM | 0.416 | 2.50 | 7.74 | 9.73 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -7.95 | 2.00 | -2.65 | -7.95 | [0 - 30] |
dividendYielPercentageTTM | 57.19 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -7.95 | 2.00 | -2.65 | -5.30 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.729 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -0.560 |
MEI Pharma Inc
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.